Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Ciltacabtagene autoleucel Inj (CDM 52599552) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 4, 2026 , from http://ppman.hank.ai/transparency/procedure/52599552/by-state?code_type=CDM
“Ciltacabtagene autoleucel Inj (CDM 52599552) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/52599552/by-state?code_type=CDM. Accessed
July 4, 2026 .
“Ciltacabtagene autoleucel Inj (CDM 52599552) by State,” HANK Price Transparency ,
accessed July 4, 2026 ,
http://ppman.hank.ai/transparency/procedure/52599552/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
52599552 — Ciltacabtagene Autoleucel Inj
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$583,076
National median
$497,281 – $681,366
IQR (p25 – p75)
11
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$236,479
vs. negotiated
-59.4%
Hospitals reporting
11
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 52599552 (CDM), with interquartile range
State Median p25 p75
IN $583,076 $497,281 $681,366